SCHEMBL159079

SCHEMBL159079

C=C(C(N)=O)C(C)(C)CC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acrylic Acid SCHEMBL26969058 0.88 LMNA (0.37) TDP1
SCHEMBL3229799 0.78 TDP1 (0.39) TDP1
SCHEMBL28124390 0.78 TDP1 (0.39) TDP1
SCHEMBL1135166 0.78 TDP1 (0.39) TDP1
SCHEMBL3775748 0.78 TET2 (0.37)
SCHEMBL9437899 0.76 GRIK1 (0.34)
SCHEMBL9437895 0.76 GRIK1 (0.34)
Ammonia Solution, Strong SCHEMBL3915936 0.76 TDP1 (0.38) TDP1
SCHEMBL10701254 0.76 LMNA (0.42) TDP1
SCHEMBL9126102 0.74 KDM4E (0.46) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 867 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085216-A1 EMULSION INCLUDING ACRYLIC POLYMER PARTICLES AND RELATED PROCESSES 3M INNOVATIVE PROPERTIES COMPANY (US) 2026-03-26 US claimed
EP-4590779-A1 EMULSION INCLUDING ACRYLIC POLYMER PARTICLES AND RELATED PROCESSES 3M Innovative Properties Company (US) 2025-07-30 EP claimed
US-20250188321-A1 FIRE-RETARDANT PRESSURE SENSITIVE ADHESIVES, ARTICLES, AND USES 3M INNOVATIVE PROPERTIES COMPANY 2025-06-12 US claimed
EP-3996692-B1 TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING AN ACTIVE AGENT-CONTAINING LAYER COMPRISING A SILICONE-CONTAINING POLYMER AND A SKIN CONTACT LAYER COMPRISING A SILICONE GEL ADHESIVE LTS LOHMANN THERAPIE SYSTEME AG (DE) 2025-06-11 EP claimed
CN-119923450-A Emulsions comprising acrylic polymer particles and related methods 3M创新有限公司 2025-05-02 CN claimed
EP-4493602-A1 COMPOSITE ADHESIVES 3M Innovative Properties Company (US) 2025-01-22 EP claimed
US-12144899-B2 Tetrabenazine transdermal delivery device SHINKEI THERAPEUTICS, INC. (US) 2024-11-19 US claimed
US-12146099-B2 Inhibition of silica scale using a chelating agent blended with acid and alkylene oxide derived polymer dispersants DOW GLOBAL TECHNOLOGIES LLC (US) 2024-11-19 US claimed
US-12138353-B2 Transdermal therapeutic system containing asenapine LTS LOHMANN THERAPIE-SYSTEME AG (DE) 2024-11-12 US claimed
CN-118829668-A Composite adhesive 3M创新有限公司 2024-10-22 CN claimed
EP-0332860-B1 Ethylene Vinyl Acetate-Dioctyl Maleate-2-Ethylhexyl Acrylate Interpolymers NAT STARCH CHEM INVEST (US) 1994-06-08 EP claimed
US-5288493-A Containing terpolymer of alkyl acrylate or methacrylate, N-substituted alkyl acrylamide, unsaturated acid NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 1994-02-22 US claimed
US-5126189-A Polymerizing, curing acrylated polyester urethanes and perfluorinated acrylates; laminating to fabric support; sterile barriers; diapers GELMAN SCIENCES, INC. (US) 1992-06-30 US claimed
WO-1991013921-A1 METHOD OF INCORPORATING HYDROPHOBIC MONOMERS INTO ACRYLAMIDE SOLUTIONS EXXON CHEMICAL PATENTS INC. (US) 1991-09-19 WO claimed
EP-0282710-B1 PRESSURE SENSITIVE ADHESIVE COMPOSITIONS FOR USE ON VINYL SUBSTRATES National Starch and Chemical Corporation (US) 1990-05-16 EP claimed
US-4906716-A Method of incorporating hydrophobic monomers into acrylamide solutions EXXON CHEMICAL PATENTS INC. (US) 1990-03-06 US claimed
EP-0271035-A2 Treatment of aqueous medium with copolymers containing acrylamidoalkane sulfonic acid THE B.F. GOODRICH COMPANY (US) 1988-06-15 EP claimed
EP-0216622-A2 Microporous membrane laminate GELMAN SCIENCES, INC. (US) 1987-04-01 EP claimed
EP-0041640-B1 PHOTOPOLYMERIZABLE COMPOSITION E.I. DU PONT DE NEMOURS AND COMPANY (US) 1985-08-28 EP claimed
US-4355091-A Polymeric neutralizing layer with temporary crosslinks from an organo-metallic crosslinking agent POLAROID CORPORATION (US) 1982-10-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12144899-B2 Tetrabenazine transdermal delivery device HTT, TTBK1, TTBK2 TDP1 467/4885
US-20260085216-A1 EMULSION INCLUDING ACRYLIC POLYMER PARTICLES AND RELATED PROCESSES ACR, SAAL1, AP2S1 TDP1 942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.